MTOR and chronic myelogenous leukemia, BCR-ABL1 positive: Carella et al. have thus demonstrated that the combination of TKIs with the antibiotic Clarithromycin, that induced accumulation of LC3-II without affecting mTOR or AKT pathways, shows remarkable responses in high-risk and advanced CML-patients [30].